Canton Strategic Holdings Inc (CNTN)

$3.26 +0.02 (0.62%)
Market Cap 184.70M
Revenue (ttm) 0.00
Net Income (ttm) -12.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 394,800
Avg Vol 954,646
Day's Range N/A - N/A
Shares Out 56.66M
Stochastic %K 44%
Beta 1.57
Analysts Strong Buy
Price Target N/A

Company Profile

Canton Strategic Holdings, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. The company also involved in research and development of GV104, a buccal film technology, which has completed Phase 1 trial for respiratory and/or nervous system depression in military personnel and chemical incident responders; and GV023, an oral formulation of infliximab, addresses a critical limitation of th...

Industry: Biotechnology
Sector: Healthcare
Phone: 732 889 3111
Address:
34 Shrewsbury Avenue, Suite 1C, Red Bank, United States
ballerallday
ballerallday Apr. 1 at 5:22 PM
$CNTN In the 8-K, they disclose that $6 million of the proceeds from the private placement went toward "non-recurring compensation" paid in connection with that specific raise. Paying out roughly 5.6% of a capital raise directly to compensation while the company is under a "Going Concern" warning is a massive governance red flag (Related Party Self-Dealing).
1 · Reply
ballerallday
ballerallday Apr. 1 at 5:20 PM
$CNTN Funny company. Couldn't make it as a biotech so they switch to a scam crypto company. Who buys stock in a company like this?
0 · Reply
CryptoLoka80
CryptoLoka80 Mar. 30 at 3:56 PM
$BTC.X $CC.X $LINK.X $SOL Canton Strategic Holdings $CNTN will post earnings Tuesday, March 31st, 2026. This is the first earnings report for CNTN formerly THAR. What will they reveal? #CantonNetwork #CC
0 · Reply
Sams1966
Sams1966 Mar. 10 at 12:38 AM
$CNTN $CNTN I see that ARK is buying this sub $5 stonk. Been hit hard lately but a lot of stocks been hit. Who is the perma bull and perma bear here?
1 · Reply
CliffordCapital
CliffordCapital Feb. 25 at 10:16 PM
$CNTN wasn’t earnings supposed to be today??
0 · Reply
bionicman1969
bionicman1969 Feb. 24 at 9:12 PM
$CNTN $BPTH cancels reverse split on 9.2MM shares as new management initiated turnaround of phase 2 leukemia cure trial with potential Blockchain applications. https://www.sec.gov/Archives/edgar/data/1133818/000166357726000046/bpth_8k022426.htm
0 · Reply
Thesandman21
Thesandman21 Feb. 20 at 11:26 PM
$CNTN this stock has been going through cycles of accumulation and gapping up. Next 2-3 months will absolutely be a $7-10 stock
0 · Reply
CliffordCapital
CliffordCapital Feb. 20 at 7:11 PM
$CNTN buy!
0 · Reply
JSP134
JSP134 Feb. 19 at 10:46 PM
$CNTN 3rd name change. Why?
0 · Reply
Sherrycat
Sherrycat Feb. 19 at 8:08 PM
$CNTN this was $THAR before, they changed their name. This was already growing as their previous ticket, I think it needs some time until everyone is up to date again🤭 lets go 🆙
0 · Reply
Latest News on CNTN
Canton Strategic Holdings Reports Full Year 2025 Financial and Operational Results

Mar 31, 2026, 8:10 AM EDT - 5 days ago

Canton Strategic Holdings Reports Full Year 2025 Financial and Operational Results

BitGo to Securely Store Digital Asset Treasury Holdings for Canton Strategic Holdings, Inc.

Mar 12, 2026, 8:00 AM EDT - 24 days ago

BitGo to Securely Store Digital Asset Treasury Holdings for Canton Strategic Holdings, Inc.

BTGO

Canton Strategic Holdings, Inc. Chairman and CEO Mark Wendland Elected to Canton Foundation Board

Mar 3, 2026, 8:15 AM EST - 4 weeks ago

Canton Strategic Holdings, Inc. Chairman and CEO Mark Wendland Elected to Canton Foundation Board

Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy

Feb 17, 2026, 7:10 AM EST - 6 weeks ago

Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy

Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

Feb 6, 2026, 8:15 AM EST - 2 months ago

Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

Feb 2, 2026, 8:15 AM EST - 2 months ago

Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

Tharimmune Announces Expanded Role as Super Validator on Canton Network

Jan 26, 2026, 8:15 AM EST - 2 months ago

Tharimmune Announces Expanded Role as Super Validator on Canton Network

Tharimmune, Inc. And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization

Jan 23, 2026, 12:34 AM EST - 2 months ago

Tharimmune, Inc. And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization

Tharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering

Jan 22, 2026, 4:12 PM EST - 2 months ago

Tharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering

Tharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering

Jan 20, 2026, 8:45 AM EST - 2 months ago

Tharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering

Tharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton Network

Dec 18, 2025, 8:15 AM EST - 3 months ago

Tharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton Network

Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy

Dec 12, 2025, 8:15 AM EST - 4 months ago

Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy

Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids

Nov 13, 2025, 8:05 AM EST - 5 months ago

Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids

Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy

Nov 6, 2025, 4:16 PM EST - 5 months ago

Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy

Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy

Nov 3, 2025, 9:04 AM EST - 5 months ago

Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy

Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl

Sep 4, 2025, 8:01 AM EDT - 7 months ago

Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl

Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments

Aug 20, 2025, 8:00 AM EDT - 8 months ago

Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments

Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl

Aug 13, 2025, 8:01 AM EDT - 8 months ago

Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl

Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors

Aug 5, 2025, 8:00 AM EDT - 8 months ago

Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors

Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery

Aug 4, 2025, 8:00 AM EDT - 8 months ago

Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

Jul 23, 2025, 10:15 PM EDT - 9 months ago

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

Jun 17, 2025, 8:01 AM EDT - 10 months ago

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

May 6, 2025, 8:01 AM EDT - 11 months ago

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

May 1, 2025, 8:01 AM EDT - 1 year ago

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

Apr 30, 2025, 8:01 AM EDT - 1 year ago

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

Apr 28, 2025, 8:01 AM EDT - 1 year ago

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

Apr 15, 2025, 9:00 AM EDT - 1 year ago

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

Apr 7, 2025, 8:00 AM EDT - 1 year ago

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Mar 4, 2025, 7:00 AM EST - 1 year ago

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Tharimmune to Present at the Microcap Conference 2025

Jan 27, 2025, 8:30 AM EST - 1 year ago

Tharimmune to Present at the Microcap Conference 2025

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Dec 16, 2024, 8:00 AM EST - 1 year ago

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Dec 6, 2024, 4:15 PM EST - 1 year ago

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Nov 18, 2024, 8:00 AM EST - 1 year ago

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Nov 13, 2024, 8:00 AM EST - 1 year ago

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Tharimmune Announces Upcoming Conference Presentations

Nov 4, 2024, 9:00 AM EST - 1 year ago

Tharimmune Announces Upcoming Conference Presentations

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Oct 28, 2024, 9:00 AM EDT - 1 year ago

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Jul 17, 2024, 8:30 AM EDT - 1 year ago

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune To Participate in Two Upcoming Investor Conferences in May

Apr 30, 2024, 8:31 AM EDT - 2 years ago

Tharimmune To Participate in Two Upcoming Investor Conferences in May

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Apr 23, 2024, 7:31 AM EDT - 2 years ago

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

Apr 15, 2024, 8:31 AM EDT - 2 years ago

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

OABI

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Mar 5, 2024, 8:31 AM EST - 2 years ago

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Feb 20, 2024, 8:01 AM EST - 2 years ago

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Feb 5, 2024, 8:30 AM EST - 2 years ago

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

ballerallday
ballerallday Apr. 1 at 5:22 PM
$CNTN In the 8-K, they disclose that $6 million of the proceeds from the private placement went toward "non-recurring compensation" paid in connection with that specific raise. Paying out roughly 5.6% of a capital raise directly to compensation while the company is under a "Going Concern" warning is a massive governance red flag (Related Party Self-Dealing).
1 · Reply
ballerallday
ballerallday Apr. 1 at 5:20 PM
$CNTN Funny company. Couldn't make it as a biotech so they switch to a scam crypto company. Who buys stock in a company like this?
0 · Reply
CryptoLoka80
CryptoLoka80 Mar. 30 at 3:56 PM
$BTC.X $CC.X $LINK.X $SOL Canton Strategic Holdings $CNTN will post earnings Tuesday, March 31st, 2026. This is the first earnings report for CNTN formerly THAR. What will they reveal? #CantonNetwork #CC
0 · Reply
Sams1966
Sams1966 Mar. 10 at 12:38 AM
$CNTN $CNTN I see that ARK is buying this sub $5 stonk. Been hit hard lately but a lot of stocks been hit. Who is the perma bull and perma bear here?
1 · Reply
CliffordCapital
CliffordCapital Feb. 25 at 10:16 PM
$CNTN wasn’t earnings supposed to be today??
0 · Reply
bionicman1969
bionicman1969 Feb. 24 at 9:12 PM
$CNTN $BPTH cancels reverse split on 9.2MM shares as new management initiated turnaround of phase 2 leukemia cure trial with potential Blockchain applications. https://www.sec.gov/Archives/edgar/data/1133818/000166357726000046/bpth_8k022426.htm
0 · Reply
Thesandman21
Thesandman21 Feb. 20 at 11:26 PM
$CNTN this stock has been going through cycles of accumulation and gapping up. Next 2-3 months will absolutely be a $7-10 stock
0 · Reply
CliffordCapital
CliffordCapital Feb. 20 at 7:11 PM
$CNTN buy!
0 · Reply
JSP134
JSP134 Feb. 19 at 10:46 PM
$CNTN 3rd name change. Why?
0 · Reply
Sherrycat
Sherrycat Feb. 19 at 8:08 PM
$CNTN this was $THAR before, they changed their name. This was already growing as their previous ticket, I think it needs some time until everyone is up to date again🤭 lets go 🆙
0 · Reply
CliffordCapital
CliffordCapital Feb. 19 at 4:15 PM
$CNTN buy
0 · Reply
barkNdunbite
barkNdunbite Feb. 19 at 2:57 PM
$CNTN SMX signal a rare entry
0 · Reply
Mike8372
Mike8372 Feb. 19 at 5:09 AM
$CNTN here here here
0 · Reply
SDk777
SDk777 Dec. 9 at 7:59 PM
@Slingshot i need short squeeze on $CNTN
0 · Reply
minamargroup
minamargroup Dec. 9 at 7:21 PM
Penny Stocks to Watch $HTGMQ $WLDS $CNTN
0 · Reply
Tigerphoenix
Tigerphoenix Dec. 9 at 7:14 PM
$CNTN This stock with low shares buying can Rip so easy ......👍🏻💪🏻
0 · Reply
DirtDvl
DirtDvl Dec. 9 at 7:09 PM
$HTGMQ I swear the after hours are gonna be EPIC....or maybe BIBLICAL!!! $CLRO $CNTN $COSM $RENT
2 · Reply
Trader9955
Trader9955 Dec. 9 at 7:06 PM
$CNTN watch the big PH spike up ⬆️📈🔥
0 · Reply
ghhhhff
ghhhhff Dec. 9 at 7:06 PM
$CNTN RNAZ heavily shorted no offering
0 · Reply
Tigerphoenix
Tigerphoenix Dec. 9 at 7:04 PM
$CNTN 🔍👀🤔💲🤑
0 · Reply
MadMaverick
MadMaverick Dec. 9 at 7:02 PM
Mid-day top gainers $AMAM 541% $HTGMQ 142% $CLRO 75% $CJJD 57% $CNTN 39%
0 · Reply
Tigerphoenix
Tigerphoenix Dec. 9 at 6:52 PM
$CNTN This will Rip . !! 🤑🤑
1 · Reply